Beyond Oocyte Retrieval: How the OPU Needle as a Platform Technology Drives Integrative Innovation in Reproductive Medicine and Frontier Research

Keywords: Multifunctional OPU Needle Platform + Intrafollicular Intervention, Microenvironment Analysis and Gene Therapy Delivery

When expanding the scope beyond conventional in vitro fertilization (IVF) cycles to the broader frontiers of reproductive medicine, the ovum pick-up (OPU) needle undergoes a fundamental evolutionary shift. No longer merely a conduit for oocyte harvesting, it has developed into an integrated interventional platform capable of deep access to the ovary-a microscopic universe-equipped with diverse functionalities. Through specialized design and functional modification, OPU needles are unlocking new horizons in fertility preservation, ovarian function regulation, mitochondrial replacement, and even gene therapy, paving the way for the future of reproductive medicine.

In ovarian tissue cryopreservation and transplantation (OTC), the OPU needle serves as a pioneer for minimally invasive biopsy. For young female cancer patients requiring urgent radiotherapy and chemotherapy, ovarian cortical biopsy and cryopreservation is a vital strategy for fertility preservation. Traditional open surgical biopsy involves substantial trauma and delays anti-cancer treatment. The modified OPU needle biopsy system enables transvaginal, ultrasound-guided sampling of multiple ovarian cortical strips (typically 3 to 5 pieces) using a 14G needle.

Studies have demonstrated that a single minimally invasive biopsy can harvest sufficient tissue containing thousands of primordial follicles, with markedly lower risks of postoperative hemorrhage and infection compared with laparoscopic surgery. Further advancements include robot-assisted precise cortical biopsy. Leveraging natural orifice transluminal endoscopic surgery (NOTES) combined with high-resolution ultrasound, OPU needles can accurately target ovarian regions with the highest follicular density for sampling, greatly enhancing the quality density of cryopreserved tissue.

For intrafollicular drug delivery and intervention, the OPU needle acts as a precise Trojan horse for localized administration. Conventional systemic medication for ovarian disorders such as premature ovarian insufficiency (POI) suffers from low therapeutic efficiency and severe side effects. Dual-lumen and triple-lumen micro-perfusion OPU needles realize localized therapy for targeted follicles: one lumen aspirates partial follicular fluid, a second injects solutions containing therapeutic agents or nutritional factors, and a third enables real-time monitoring of intrafollicular pressure.

In animal trials, intrafollicular delivery of growth factors (including BMP-15 and GDF-9) or autophagy inhibitors via this approach significantly improves oocyte quality and delays follicular atresia. In in vitro maturation (IVM) cycles, targeted injection of small doses of maturation-promoting factors into small and medium-sized follicles 24 hours prior to retrieval markedly elevates the in vitro maturation rate and subsequent developmental potential of immature oocytes.

In mitochondrial replacement therapy (MRT), the OPU needle evolves into a nanoscale scalpel for organelle transplantation. For women with severe genetic disorders caused by mitochondrial DNA mutations, MRT, also known as the three-parent baby technique, requires transplanting the patient's oocyte nucleus into the enucleated cytoplasm of a healthy donor oocyte. This procedure demands ultra-precise micromanipulation needles with tip diameters of merely 5–7 μm, driven by piezoelectric ceramics to achieve nanometer-scale movement. While not conventional OPU retrieval needles, these instruments originate from the micromanipulation principles of OPU technology and operate on identical laboratory platforms. Future integrated systems may combine nucleus extraction and healthy mitochondrial injection into a single device, completing therapeutic intervention in one minimally invasive procedure.

In ovarian microenvironment research and liquid biopsy, the OPU needle provides an invaluable sampling window. Analysis of cell-free DNA, RNA, exosomes and metabolites within follicular fluid enables non-invasive assessment of ovarian reserve, oocyte quality, and even diagnosis of conditions including endometriosis and ovarian cancer. Specialized research-grade OPU needles are coated with RNase-inhibiting layers and paired with pre-cooled collection tubes to maximally preserve the integrity of biomolecules in follicular fluid during oocyte retrieval. By comparing molecular profiles of follicular fluid from different follicles within the same patient, researchers can investigate inter-follicular heterogeneity and biomarkers associated with oocyte developmental potential, providing evidence for personalized oocyte selection.

In explorations of gene therapy and germ cell editing, the OPU needle represents a potential delivery pathway. For hereditary infertility arising from single-gene mutations (such as certain oogenesis disorders), intrafollicular delivery of gene-editing tools including the CRISPR-Cas9 system is theoretically viable for therapeutic intervention. OPU needles integrated with nanocarriers are currently under investigation. The conceptual design involves needle tips coated or internally loaded with nanoparticle or viral vectors carrying therapeutic genes. Upon follicular puncture, these vectors are released and internalized by granulosa cells or oocyte precursors, enabling in vivo correction of genetic defects. Although substantial technical and ethical challenges remain, this approach embodies the ultimate paradigm of precision reproductive intervention.

In the future, the OPU needle will evolve into a comprehensive ovarian diagnosis and treatment platform. A foreseeable clinical scenario unfolds as follows: an intelligent multifunctional needle enters the ovary under ultrasound guidance. First, its integrated miniature optical coherence tomography (OCT) probe performs in situ imaging assessment of follicular walls and oocytes. Next, nanosensors analyze the metabolic profile of follicular fluid. Based on real-time diagnostic results, the system autonomously determines the optimal procedure: direct oocyte aspiration, prior localized drug perfusion intervention, or preliminary granulosa cell sampling for genetic analysis followed by retrieval. All data is synchronously uploaded to cloud servers, integrated with the patient's genomic and metabolomic datasets, to facilitate AI-assisted formulation of optimal oocyte management and therapeutic regimens.

This platform-oriented evolution of the OPU needle marks a profound transition in assisted reproductive technology, shifting from macroscopic manipulation (harvesting and handling gametes and embryos) toward microscopic intervention (modulation of follicular microenvironment and cellular function remediation). It empowers reproductive specialists not only to utilize existing oocytes, but also to improve, repair, and even enhance oocyte developmental potential. This slender instrument, once a simple tool at the origin of human life, is growing into a pivotal bridge connecting the present and future, therapy and enhancement, as well as clinical reality and untapped possibilities.